Better education on screening required for widespread use of teplizumab in type 1 diabetes treatment
Teplizumab (Tzield, Sanofi) may delay the onset of type 1 diabetes (T1D), but barriers to treatment may affect adherence to the medication. Increased screening opportunities and education about these programs…